Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02693860 · ClinicalTrials.gov registry record · Phase 1
Neoadjuvant J591 Treatment for Prostate Cancer
A Phase 1 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02693860 is a Phase 1 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 8 participants.
The verdict
NCT02693860, a Phase 1 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
10 patients will be enrolled in the initial cohort and will receive two infusions of unlabeled huJ591 on days 1 and 14. 89Zr-J591 will be administered on day 21 (+ 1 day) and a positron emission tomography-computed tomography (PET/CT) will be performed week later on day 28 + 1 (visit 4). Approximately 2 to 3 weeks after the 2nd dose of J591, the patient will undergo radical prostatectomy with or without lymph node dissection (day 31 + 4 days). The final visit for the study will include a postoperative visit two weeks following surgery.
Interventions
- DRUG huJ591
- DRUG 89Zr-J591
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-02-04 |
| Est. Completion | 2020-02-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02693860
The ClinicalTrials.gov registry entry for NCT02693860 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which huJ591 is the first listed.
NCT02693860 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02693860 about?
NCT02693860 is a clinical study titled "Neoadjuvant J591 Treatment for Prostate Cancer". 10 patients will be enrolled in the initial cohort and will receive two infusions of unlabeled huJ591 on days 1 and 14. 89Zr-J591 will be administered on day 21 (+ 1 day) and a positron emission tomography-computed tomography (PET/CT) will be performed week later on day 28 + 1 (visit 4). Approximate...
What is the current status of trial NCT02693860?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2016-02-04. Estimated completion is 2020-02-02.
What interventions are being tested in trial NCT02693860?
The interventions under investigation include: huJ591 (DRUG), 89Zr-J591 (DRUG).
Who is sponsoring clinical trial NCT02693860?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.